← All trials
NCT07258173
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2026
- Primary completion
- May 15, 2026
- Completion date
- May 15, 2026
- First posted
- Dec 2, 2025
- Last posted
- Dec 2, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BaselLead sponsor
- BayerCollaborator
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)Collaborator
- University of BaselSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.